Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUINTESSENTIAL-2
2024-515279-37-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Apr 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 31
01
Overview
Phase 3, randomised, open-label trial of arlocabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Progression-free survival and Minimal residual disease-negative complete response. Planned start Apr 2025; status: authorised.
02
Drugs
arlocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-515279-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515279-37-00.